]

TBAJ-876

Background:

In animal models, this diarylquinoline appears more efficacious and potent against TB than bedaquiline as well as the investigational diarylquinoline TBAJ-587, with a lower predicted clinical dose than either of those compounds. Similar to TBAJ-587, TBAJ-876 possesses improved safety properties compared to bedaquiline.

Phase 1

Trial Components

Solo Compounds